Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables (2016 - 2026)

OptimizeRx's Receivables history spans 16 years, with the latest figure at $41.7 million for Q4 2025.

  • On a quarterly basis, Receivables rose 0.58% to $41.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.7 million, a 0.58% increase, with the full-year FY2025 number at $41.7 million, up 0.58% from a year prior.
  • Receivables hit $41.7 million in Q4 2025 for OptimizeRx, up from $35.9 million in the prior quarter.
  • Over the last five years, Receivables for OPRX hit a ceiling of $42.3 million in Q4 2023 and a floor of $757218.0 in Q3 2021.
  • Historically, Receivables has averaged $23.0 million across 5 years, with a median of $25.1 million in 2022.
  • Biggest five-year swings in Receivables: tumbled 94.32% in 2021 and later surged 724.22% in 2024.
  • Tracing OPRX's Receivables over 5 years: stood at $26.9 million in 2021, then dropped by 4.36% to $25.7 million in 2022, then skyrocketed by 64.46% to $42.3 million in 2023, then dropped by 2.07% to $41.5 million in 2024, then grew by 0.58% to $41.7 million in 2025.
  • Business Quant data shows Receivables for OPRX at $41.7 million in Q4 2025, $35.9 million in Q3 2025, and $37.0 million in Q2 2025.